tp mainli due lower tax rate
eye like upcom elanco exchang offer overal
mix revenu beat expect ep miss forecast penni
updat guidanc also move part new rang
better model believ alreadi
incorpor loxo lartruvo although larg driven lower tax rate
expect lilli announc plan complet exchang offer
remain share still own wait final
detail believ like drive near-term movement share
fundament basi continu see lilli solid well-
diversifi stori run well-respect manag team also
take note signific premium stock trade rel peer
pe vs peer keep us neutral rate stock
notabl model chang increas sale forecast product
trulic jardianc taltz mainli off-set reduct
make estim product basaglar olumi
verzenio also lower tax rate beyond
given continu impact tax reform main driver
dcf target price increas ep increas
valuat risk target price increas
base sum-of-the-part consist lilli elanco
anim health busi pharma busi valu
pharma busi base dcf valuat appli
wacc along perpetu growth forecast main risk
target price neutral rate better/wors expect
commerci execut and/or surpris clinic data pipelin
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
co discov develop manufactur sell
pharmaceut product human anim manufactur
distribut product facil us puerto rico
countri
price feb rate neutral target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
trulic jardianc taltz emgal olumi verzenio
compar current base case assumpt also model higher
gross margin oper margin base case
assumpt blue sky valuat base dcf driven
wacc termin valu assign lilli share
elanco per share
grey sky valuat base lower sale trulic
jardianc taltz emgal olumi verzenio compar
current base case assumpt grey sky valuat base
dcf driven wacc termin valu assign
lilli share elanco per share
 close
note follow-up call ir
opportun speak member ir team follow morn
earn call gain addit clariti result updat guidanc
summar compani answer question
much trulic sale come pcp vs endocrinologist trulic market
share rel victoza differ pcp endocrinologist
 mayb littl strength primari care given advantag trulic
pcps/endocrinologist rel stabl past quarter
 class growth remain key
growth class trulic also gain share
first inject market go closer look
price environ basaglar
high barrier entri other enter basal market
driven volum growth includ better access part
yoy volum growth well
around new therapi start littl
happi progress date
access pretti similar expect major chang compar
steadi
basal insulin class continu grow low-middl singl digit yoy base
clarifi patent expir date key diabet asset
tradjenta com patent expir may
jardianc com patent expir us aug pend
trulic com patent expir juli dec pend extens
sale growth lag prescript growth prescript growth
us fy sale growth
drive volum psoriasi gain traction new indic psoriat
spread script sale growth less look vs
vs
 spread wider driven get patient drug patient
addit thought expect term need imag patient
therapi reason assumpt durat use one
expect tanezumab
need see total data
 oa patient cycl lot differ med
 data help determin durat use
time addit data
phase data
 os trial power os
adjuv
high risk adjuv trial oppos mod-high risk
verzenio particularli well patient poor prognosis/high risk patient
also way potenti speed trial data readout
trial enrol well data potenti within month ibranc
how/when get detail
mention need complet within year provid tighter
rang get closer end lock-up period
expect full pharma guidanc includ ep
close transact
reduct week prior guidanc
adjust relat greater understand impact us tax reform
reason tax rate beyond much differ
reason assumpt think sustain
sale
sale
us million except per share data
updat expect lartruvo partial
off-set loxo acquisit trend core
addit loxo onc develop portfolio
increas interest expens loxo
adjust us tax reform
updat expect lartruvo impact
loxo acquisit partial off-set trend
core busi improv tax rate
note assum elanco minor interest entireti loxo acquisit close
us million except per share data
sale
total incom expens
provis incom tax
figur revenu statement
figur revenu statement
compani mention price
